NEW YORK, NY -- (Marketwire) -- 01/09/12 -- Stem Cell stocks -- particularly companies focused on adult stems cells -- have performed well of late. Earlier this month Goldman Sachs noted the potential upside of Pluristem Therapeutics -- noting that the company does not use the highly controversial embryonic stem cells. The remark from the analyst firm helped drive shares of similar companies that use adult stem cells. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Advanced Cell Technology, Inc. (OTCBB: ACTC) and Cord Blood America, Inc. (OTCBB: CBAI). Access to the full company reports can be found at:
www.paragonreport.com/ACTC
www.paragonreport.com/CBAI
Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. In late December, the company announced that it signed an exclusive agreement to store stem cells at its Las Vegas laboratory for the National Children's Leukemia Foundation (NCLF), New York.
Cord blood stem cells are presently used to treat 75 diseases including leukemia, severe anemia, metabolic blood disorders and immune deficiencies, with ongoing research worldwide to treat many of the world's most serious diseases, including diabetes, heart disease and stroke.
The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.
Advanced Cell Technology, Inc. applies stem cell-based technologies (both adult and human embryonic) and other proprietary methods in the field of regenerative medicine. In a recent "blog from the chairman" on the company's website, Gary Rabin observes that Advanced Cell Technology now has the distinction of being the only company that is conducting FDA-cleared human clinical trials using human embryonic stem cell-derived therapies. "Both of our ongoing Phase 1/2 trials use human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells, one for Stargardt's macular dystrophy (SMD) and the other for dry age-related macular degeneration (dry AMD)," Rabin explains.
The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
